Journal
JOURNAL OF CONTROLLED RELEASE
Volume 354, Issue -, Pages 770-783Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2023.01.043
Keywords
Aluminum adjuvants; Tumor microenvironment; Layered double hydroxide; Metalloimmunotherapy; In situ immunotherapy
Ask authors/readers for more resources
Researchers developed a nano-aluminum adjuvant, NanoAlum, which successfully inhibited the growth of solid tumors in mice. NanoAlum, injected around the tumor, neutralized the acidic tumor microenvironment and activated tumor-resident T cells. It also inhibited the autophagy pathway in tumor cells, leading to cell apoptosis.
The poor cancer immunotherapy outcome has been closely related to immunosuppressive tumor microenvironment (TME), which usually inactivates the antitumor immune cells and leads to immune tolerance. Metalloimmunotherapy by supplementing nutritional metal ions into TME has emerged as a potential strategy to activate the tumor-resident immune cells. Herein, we engineered a magnesium-contained nano-aluminum adjuvant (NanoAlum) through hydrolyzing a mixture of Mg(OH)2 and Al(OH)3, which has highly similar components to commercial Imject Alum. Peritumoral injection of NanoAlum effectively neutralized the acidic TME while releasing Mg2+ to activate the tumor-resident T cells. Meanwhile, NanoAlum also blocked the autophagy pathway in tumor cells and subsequently induced cell apoptosis. The in vivo studies showed that merely peritumoral injection of NanoAlum successfully inhibited the growth of solid tumors in mice. On this basis, NanoAlum combined with chemical drug methotrexate or immunomodulatory adjuvant CpG further induced potent antigen-specific antitumor immunity. Overall, our study first provides a rational design for engineering tumortargeted nanomodulator from clinical adjuvants to achieve effective cancer metalloimmunotherapy against solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available